Evaluation of homologous recombination deficiency (HRD) status with pathological response to carboplatin +/- veliparib in BrighTNess, a randomized phase 3 study in early stage TNBC.
Work
Year: 2018
Type: article
Source: Journal of Clinical Oncology
Institutions Stanford University, Dana-Farber Cancer Institute, Myriad Genetics, AbbVie (United States), Yonsei University +6 more
Cites:
Cited by: 35
Related to: 10
FWCI: 2.523
Citation percentile (by year/subfield): 88.74
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Sustainable Development Goal Good health and well-being
Open Access status: closed